Case Study: Global Pharma Company reduces disease relapse risk with Quantzig's clinical trial data analysis

Clinical Trial Data Analysis Engagement Helped a Leading Global Pharma Company to Determine Chance of Disease Relapse

Global Pharma Company partnered with Quantzig to analyze clinical trial data from melanoma patients treated across more than 10 hospitals. The company needed help comparing two treatment groups to assess disease-free interval, survival, recurrence risk, and factors affecting survival, after struggling with the complexity and completeness of raw patient data.

Quantzig implemented a three-phase clinical trial data analysis engagement that included business requirement discovery, data integration and quality reporting, and advanced survival modeling using parametric hazard models, life tables, and log-rank tests. As a result, Global Pharma Company gained insights into adverse events and patient characteristics, improved its data quality checks, reduced the risk of multiple surgeries, and was better able to predict the optimal therapy line and evaluate medication effectiveness.